Correction of erectile dysfunction in patients with BPH using daily administration of tadalafil 5 mg against the background of combined drug. therapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The study included 59 patients with benign prostate hyperplasia (BPH) and erectile dysfunction (ED), inhibited inflammation in the prostate gland and with normal or medically normalized levels of total testosterone. All the patients underwent conservative therapy using dutasteride and tamsulosin, 21 of them (group 2) additionally received tadalafil 5 mg daily. Efficacy of treatment was assessed by self-assessment questionnaire of patients before treatment and 12 weeks after therapy. In group 1 of patients, the dynamics of the erectile function, sexual satisfaction and quality of life for patients was not revealed. In the group 2, improvement in erectile function in an average of 19 points was shown (IIEF-5 questionnaire). According to the AMS questionnaire, improvement in sexual function was demonstrated; in patients with compensated androgen deficiency, however, response to the treatment with tadalafil was less pronounced. According to BSFI score after 3 months of therapy with tadalafil, indicator of overall satisfaction of sexual life improved to 2.4 points (p<0,002). According to the Hospital Anxiety and Depression Scale, anxiety in patients was reduced to the permissible values (p<0,0002), the level of depression was decreased by almost 2-fold (p <0,0002). The total IPSS score decreased from 13 to 9 points in average. The inclusion of tadalafil in complex of combined conservative therapy of patients with BPH not only improves sexual function but has a positive effect on symptoms of the disease and the psychological state of the patient.

Full Text

Restricted Access

References

  1. Roehrborn C.G., Briganti A., Capitanio U. et al. Benign prostatic hyperplasia and Its Aetiologies. Eur. Urol. 2009;(Suppl. 8): 865-871.
  2. Kirby R. Improving lower urinary tract symptoms in BPH. The Practitioner 2011;255(1739):15.
  3. Roehrborn C.G., Siami P., Barkin J. et al. The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study. Eur. Urol. 2010;57:123-131.
  4. Donnell R.F. Benign prostate hyperplasia: a review of the year's progress from bench to clinic. Curr. Opin. Urol. 2011;21(1):22—26.
  5. Mondul A.M., Rimm E.B., Giovannucci E. et al. A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction. J Urol. 2008;179(6):2321-2326.
  6. Inge I. Bouwman, Wouter K. Van Der Heide et al. Correlations between lower urinary tract symptoms, erectile dysfunction, and cardiovascular diseases: Are there differences between male populations from primary healthcare and urology clinics? The European journal of general practice. Nov 2009;15(3):128-135.
  7. Calais Da Silva F., Marquis P., Deschaseaux P. et al. Relative impotance of sexuality and quality of life in patients with prostatic symptoms. Eur. Urol. 1997;31(3):271-280.
  8. Пушкарь Д.Ю., Берников А.Н., Живов А.В. Эффективность, безопасность и перспективы длительного использования препарата Сиалис (тадалафил) в режиме один раз в день у пациентов с эректильной дисфункцией. Обзор литературы. РМЖ. Урология. 2011;19(4):3-6.
  9. Broderick G.A., Brock G.B., Roehrborn C.G. et al. Effects of Tadalafil on Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in men with or without erectile dysfunction. Urology. 2010;75(6):1452—1458.
  10. Montrosi F., Aversa A., Moncada I. et al. A randomized, doubleblind, placebo-controlled, parallel study to asses the efficacy and safety of once-daily tadalafil in men with erectile function who are naïve to PDE 5 ingibitors. J Sex Med. 2011; 8(9):2617-2624.
  11. Donatucci C.F., Brock G.B., Goldfischer E.R. et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int. 2011;107 (7): 1110-1116.
  12. Seftel A., Goldfischer E., Kim E.D. et al. Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo-controlled trial. J Urol. 2011; 185(1): 243-248.
  13. Egerdie R.B., Auerbach S., Roehrborn C.G. et al. Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in men with both erectile dysfunction and signs and symptoms of benign Prostatic Hyperplasia: Results of a Randomized, Placebo-Controlled, Double-Blind study.J Sex Med. 2012; 9(1): 271-281.
  14. Porst H., Kim E.D., Casaber A.R. et al. Efficacy and safety of once daily in the treatment of men with lower urinary tract symptoms suggestive of benign rostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur. Urol. 2011; 60(5):1105-1113.
  15. McVary K.T., Roehrborn C.G., Kaminetsky J.C. et al. Tadalafil relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Urology. 2007;177(4):1401-1407.
  16. Roehrborn C.G., Kaminetsky J.C., Auerbach S.M. Changes in peak urinary flow and voiding benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int. 2010;105(4):502-507.
  17. Oelke M., Giuliano F., Mirone V. et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur. Urol. 2012;61(5): 917-925.
  18. Porst H., McVary K.T., Montorsi F. et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur. Urol. 2009; 56(4):727-35.
  19. Park N.C. Combination therapy with dutasteride and tadalafil in men with moderete-to-severe benign prostatic hyperplasia. Eur. Urol. Suppl. 2013;12.e1092.
  20. Casabt A.R. et al. Combination therapy with finasteride and tadalafil once daily for 6 months in men with LUTS secondary to benign prostatic hyperplasia. Eur. Urol. Suppl. 2013.12. e1096.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies